Challenges and progress in the development of a serogroup B meningococcal vaccine.
Serogroup B meningococci cause the majority of the meningococcal disease burden in developed countries. Production of an effective and safe vaccine for serogroup B organisms has been hampered by the poor immunogenicity of the capsular polysaccharide that defines this group of bacteria. Previous effo...
| Main Authors: | , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2009
|
| _version_ | 1826277658331185152 |
|---|---|
| author | Lewis, S Sadarangani, M Hoe, J Pollard, A |
| author_facet | Lewis, S Sadarangani, M Hoe, J Pollard, A |
| author_sort | Lewis, S |
| collection | OXFORD |
| description | Serogroup B meningococci cause the majority of the meningococcal disease burden in developed countries. Production of an effective and safe vaccine for serogroup B organisms has been hampered by the poor immunogenicity of the capsular polysaccharide that defines this group of bacteria. Previous efforts have focused on outer membrane vesicle vaccines, which have been implemented successfully during clonal outbreaks. However, the search for a universal vaccine against endemic polyclonal serogroup B meningococcal disease continues. In this review, we have highlighted recent development of outer membrane vesicle vaccines and progress in the evaluation of recombinant outer membrane protein vaccines. |
| first_indexed | 2024-03-06T23:32:13Z |
| format | Journal article |
| id | oxford-uuid:6c6f9f58-8ae7-4c8f-a0c9-1127d0d74027 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:32:13Z |
| publishDate | 2009 |
| record_format | dspace |
| spelling | oxford-uuid:6c6f9f58-8ae7-4c8f-a0c9-1127d0d740272022-03-26T19:10:48ZChallenges and progress in the development of a serogroup B meningococcal vaccine.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6c6f9f58-8ae7-4c8f-a0c9-1127d0d74027EnglishSymplectic Elements at Oxford2009Lewis, SSadarangani, MHoe, JPollard, ASerogroup B meningococci cause the majority of the meningococcal disease burden in developed countries. Production of an effective and safe vaccine for serogroup B organisms has been hampered by the poor immunogenicity of the capsular polysaccharide that defines this group of bacteria. Previous efforts have focused on outer membrane vesicle vaccines, which have been implemented successfully during clonal outbreaks. However, the search for a universal vaccine against endemic polyclonal serogroup B meningococcal disease continues. In this review, we have highlighted recent development of outer membrane vesicle vaccines and progress in the evaluation of recombinant outer membrane protein vaccines. |
| spellingShingle | Lewis, S Sadarangani, M Hoe, J Pollard, A Challenges and progress in the development of a serogroup B meningococcal vaccine. |
| title | Challenges and progress in the development of a serogroup B meningococcal vaccine. |
| title_full | Challenges and progress in the development of a serogroup B meningococcal vaccine. |
| title_fullStr | Challenges and progress in the development of a serogroup B meningococcal vaccine. |
| title_full_unstemmed | Challenges and progress in the development of a serogroup B meningococcal vaccine. |
| title_short | Challenges and progress in the development of a serogroup B meningococcal vaccine. |
| title_sort | challenges and progress in the development of a serogroup b meningococcal vaccine |
| work_keys_str_mv | AT lewiss challengesandprogressinthedevelopmentofaserogroupbmeningococcalvaccine AT sadaranganim challengesandprogressinthedevelopmentofaserogroupbmeningococcalvaccine AT hoej challengesandprogressinthedevelopmentofaserogroupbmeningococcalvaccine AT pollarda challengesandprogressinthedevelopmentofaserogroupbmeningococcalvaccine |